Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed at studying quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) formulations in Toddlers.

Primary Objectives: Safety and Immunogenicity:

To describe the safety and immunogenicity profiles of:

* A single dose of each formulation of TetraMen-T vaccine
* A single dose of NeisVac-C® vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

NCT02955797

Meningitis Meningococcal Meningitis Meningococcal Infections

COMPLETED PHASE3

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035

Meningitis Meningococcal Infection

COMPLETED PHASE2

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

NCT00643916

Meningitis Meningococcal Infection

COMPLETED PHASE2

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT03205358

Meningitis Meningococcal Meningitis Meningococcal Infections

COMPLETED PHASE2

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438

Meningitis Meningococcal Meningitis Meningococcal Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed to evaluate the safety profile and the immunogenicity response after a single dose of TetraMen-T in toddlers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningitis Meningococcal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Group Type EXPERIMENTAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Group 2

Group Type EXPERIMENTAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Group 3

Group Type EXPERIMENTAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Group 4

Group Type EXPERIMENTAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Group 5

Group Type EXPERIMENTAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Group 6

Group Type ACTIVE_COMPARATOR

Meningococcal polysaccharide group C conjugated

Intervention Type DIETARY_SUPPLEMENT

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meningococcal Polysaccharide Tetanus Protein Conjugate

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Meningococcal Polysaccharide Tetanus Protein Conjugate

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Meningococcal polysaccharide group C conjugated

0.5 mL, Intramuscular

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NeisVac-C® vaccine (Baxter Healthcare)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is healthy, as determined by medical history and physical assessment.
* Aged 12 months (± 21 days) on the day of inclusion.
* Institutional Review Board (IRB)-approved informed consent form signed by the subject's parent/legal guardian.
* Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria

* Serious acute or chronic disease (e.g., cardiac, renal, metabolic, rheumatologic, psychiatric, hematologic, or autoimmune disorders, diabetes, atopic conditions, congenital defects, convulsions, encephalopathy, blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic system, acute untreated tuberculosis) that could interfere with trial conduct or completion.
* Known or suspected impairment of immunologic function.
* Acute medical illness within the last 72 hours, or temperature ≥ 37.5ºC (axillary) at the time of enrollment (temporary contraindication).
* History of documented invasive meningococcal disease or previous meningococcal vaccination.
* Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C seropositivity as reported by the parent or legal guardian.
* Received either immune globulin or other blood products within the last 3 months, or received injected or oral corticosteroids or other immunomodulator therapy within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. Topical steroids are not included in this exclusion criterion.
* Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to the study blood draw. Topical antibiotics or antibiotic drops are not included in this exclusion criterion.
* Suspected or known hypersensitivity to any of the vaccine components.
* Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM) vaccination.
* Parent or legal guardian unable or unwilling to comply with the stu dy procedures.
* Participation in another interventional clinical trial in the 30 days preceding enrollment, or participation in another clinical trial involving the investigation of a drug, vaccine, medical procedure, or medical device during the subject's trial period.
* Diagnosed with any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
* Received any vaccine in the 30-day period prior to receipt of study vaccine, or scheduled to receive any vaccination other than influenza vaccination and hyposensitization therapy in the 30-day period after receipt of any study vaccine. Hyposensitization therapy and influenza vaccination may be received up to 14 days before or 14 days after receiving the study vaccines.
* History of seizures, including febrile seizures, or any other neurologic disorder.
* Personal or family history of Guillain-Barré Syndrome (GBS).

Minimum Eligible Age

12 Months

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes